BridgeMD
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib
EU CTIS ID: 2024-512982-15-00
What this study is testing
To provide continuous study treatment to patients who continue to benefit at the end of a clinical trial, while monitoring safety and tolerability
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1 Provision of signed and dated, written ICF.
- 2 Patient is currently deriving clinical benefit, as judged by the Investigator, from continued treatment in an AZ parent study using an AstraZeneca (AZ) compound that has met its endpoints or has otherwise stopped.
- 3 Patient participating in a prior oncology study with an AZ compound in which they received olaparib and are continuing to receive clinical benefit from treatment; the prior study can be an open-label or blinded study, with unblinding at study close.
You likely can't join if
- 1 Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study.
- 2 Currently receiving treatment with any prohibited medication(s).
- 3 Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- 4 Permanent discontinuation from the parent study due to toxicity or disease progression (increase in the severity of the disease under study and/or increases in the symptoms of a patient's condition attributable to the disease, as assessed and documented by the Investigator. Physician-defined progression can be radiological [eg, RECIST] progression or clinical progression).
- 5 Local access to commercially-available drug at no cost to the patient, as permitted by local/country regulation.
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- Korea, Republic of
- Taiwan
- Russian Federation
- United States
- Brazil
- Israel
- Canada
- China
- Turkey
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; Korea, Republic of; Taiwan; Russian Federation; United States; Brazil and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.